CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


COVID-19 Convalescent Plasma (CCP)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2739 anti-SARS-CoV-2 convalescent plasma Wiki 0.50
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients

The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.

NCT04421404 COVID-19 Sars-CoV2 Biological: COVID-19 Convalescent Plasma (CCP) Biological: Placebo
MeSH:Coronavirus Infections

Primary Outcomes

Description: Progression to mechanical ventilation or death within the first 14 days of enrollment.

Measure: Mechanical Ventilation or Death Endpoint

Time: Day 14

Secondary Outcomes

Description: Progression to mechanical ventilation or death within the first 28 days of enrollment.

Measure: Mechanical Ventilation or Death Endpoint

Time: Day 28

Description: Clinical efficacy of CCP relative to the control arm in adults hospitalized with COVID-19 according to clinical status as assessed by 8-point ordinal scale. Death; Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities.

Measure: 8-Point Ordinal Scale Endpoint

Time: Day 29


No related HPO nodes (Using clinical trials)